Amphista Therapeutics begins first human trial of AMX-883 BRD9 degrader in acute myeloid leukemia
Amphista begins its 54-patient AMX-883 Phase 1 trial in AML and high-risk MDS. Examine the novel BRD9 mechanism, safety tests and next milestones.
Pharma & Biotech